Fred Hagen, Ph.D.

Fred Hagen, Ph.D.

Contact Information

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 712
Rochester, NY 14642

Office: (585) 275-0336
Fax: (585) 276-0190
Lab: (585) 275-0380

Research Bio

We study glycosylation because multi-cellular organisms have evolved hundreds of gene products that are involved in post-translational modification of the cell surface. Cell surface molecules mediate cell-cell interactions, signaling events and structures that are important for development of tissues and organs. Defects in the post-translational modification machinery result in severe inherited disorders. The most prevalent class of cell-surface molecules are glycoconjugates, which are proteins, lipids or carbohydrates that are modified with sugar chains (oligosaccharides). In mass terms, the saccharide component of a glycoprotein can account for up to 85% of its molecular weight. In terms of complexity, literally millions of different complex carbohydrate side chains can be synthesized, and these are expressed in tissue-specific patterns throughout development.



The role of carbohydrate chain modification in development, however, has not been closely examined for hundreds of glycosyltransferase genes. For this reason the study of glycosylation in development is in its infancy. We hypothesize that many different classes of oligosaccharides on the cell surface are crucial for orchestrating development processes because many unique glycoconjugate structures are expressed in specific temporal and spatial patterns throughout development.

A Comprehensive Functional Genomics Screen of Glycosyltransferases. Our objective is to identify every member of the glycosyltransferase superfamily, using motif modeling and searching strategies. Each of these glycosyltransferases will be cloned and targeted in a reverse genetic screen to identify those glycosyltransferases that are critical for development. We believe that C. elegans is best suited for a comprehensive genomics approach because it is a very simple organism, composed of about 1000 somatic cells, in which the complete cell lineage is known at single cell resolution. Furthermore, C. elegans is amenable to genetic manipulation and rapid RNA interference screens. These features will allow us to screen each glycosyltransferase gene for a loss-of-function phenotype. Those glycosyltransferases that are critical of development will then be characterized biochemically and structurally so that we can work on the interface of biology and biochemistry to elucidate important novel mechanisms in development.

Awards & Honors (Local)

University of Rochester Nominee to Searle Scholars Program 1998
NIDR: Oral Cellular and Molecular Biology Research Training Grant, University of Rochester 1991 - 1992
Graduate Assistantship (TRUST), Faculty of Medicine Trust Fund, U. Calgary, Alberta, Canada 1989
Tuition Fee Scholarship, U. Calgary, Alberta, Canada, Graduate Studies 1985 - 1987
Alberta Heritage Foundation for Medical Research Studentship, U. Calgary, Alberta, Canada 1984 - 1988
NATO Travel Grant/Faculty of Medicine Summer Studentship, U. Calgary, Alberta, Canada 1983
Max Planck Fellowship, Max Planck Institut, W. Germany 1983
California Foundation for Biochemical Research Fellowship, University of California, Davis 1981
DAAD (German Academic Exchange), Max Planck Institut, W. Germany 1981 - 1983
President's Undergraduate Fellowship, University of California, Davis Independent Study 1980

Recent Journal Articles

Showing the 5 most recent journal articles. 40 available »

2014 Apr
Nadtochiy SM, Madukwe J, Hagen F, Brookes PS. "Mitochondrially targeted nitro-linoleate: a new tool for the study of cardioprotection." British journal of pharmacology.. 2014 Apr; 171(8):2091-8.
2014 Feb 14
Beckham CJ, Olsen J, Yin PN, Wu CH, Ting HJ, Hagen FK, Scosyrev E, Messing EM, Lee YF. "Bladder Cancer Exosomes Contain EDIL-3/Del1 and Facilitate Cancer Progression." The Journal of urology.. 2014 Feb 14; Epub 2014 Feb 14.
2013 Nov 22
Pei S, Minhajuddin M, Callahan KP, Balys M, Ashton JM, Neering SJ, Lagadinou ED, Corbett C, Ye H, Liesveld JL, O'Dwyer KM, Li Z, Shi L, Greninger P, Settleman J, Benes C, Hagen FK, Munger J, Crooks PA, Becker MW, Jordan CT. "Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells." The Journal of biological chemistry.. 2013 Nov 22; 288(47):33542-58. Epub 2013 Oct 02.
2012 Jul 13
Miralem T, Lerner-Marmarosh N, Gibbs PE, Tudor C, Hagen FK, Maines MD. "The human biliverdin reductase-based peptide fragments and biliverdin regulate protein kinase C? activity: the peptides are inhibitors or substrate for the protein kinase C." The Journal of biological chemistry.. 2012 Jul 13; 287(29):24698-712. Epub 2012 May 14.
2012 Jan 2
Wangler NJ, Santos KL, Schadock I, Hagen FK, Escher E, Bader M, Speth RC, Karamyan VT. "Identification of membrane-bound variant of metalloendopeptidase neurolysin (EC 3.4.24.16) as the non-angiotensin type 1 (non-AT1), non-AT2 angiotensin binding site." The Journal of biological chemistry.. 2012 Jan 2; 287(1):114-22. Epub 2011 Oct 28.

Current Appointments

Research Assistant Professor (Part-Time) - Department of Biochemistry and Biophysics (SMD) - Primary

Education

PhD | Biochemistry | Canada-U Calgary Fac Med1989
BS | Biochemistry | Univ of Cal Davis1981

Post-Doctoral Training & Residency

University of Rochester, Department of Dental Research (Supervisor: Dr. L. Tabak; Topic: Molecular Biology of O-glycosylation) 1992